BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib and dasatinib are currently the first‐line agents for the treatment of CML.4 Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.